Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.
Garcia-Vidal C, Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, Marcos MA, Ambrosioni J, Bodro M, Chumbita M, de la Mora L, Garcia-Pouton N, Dueñas G, Hernandez-Meneses M, Inciarte A, Cuesta G, Meira F, Morata L, Puerta-Alcalde P, Herrera S, Tuset M, Castro P, Prieto-Gonzalez S, Almuedo-Riera A, Mensa J, Martínez JA, Sanjuan G, Nicolas JM, Del Rio A, Muñoz J, Vila J, Garcia F, Soriano A; Hospital Clinic of Barcelona COVID-19 Research Group.
Garcia-Vidal C, et al.
J Antimicrob Chemother. 2021 Nov 12;76(12):3296-3302. doi: 10.1093/jac/dkab321.
J Antimicrob Chemother. 2021.
PMID: 34473275
Free PMC article.